Author: GlobeNewswire

Earlier this year FDA granted REVASCOR both Rare Pediatric Disease Designation (RPDD) and Orphan-Drug Designation (ODD) for congenital heart diseaseNEW…

Jupiter, Florida, Dec. 04, 2024 (GLOBE NEWSWIRE) — Jupiter Neurosciences, Inc. (Nasdaq: JUNS) (the “Company” or “Jupiter Neurosciences”), a clinical…

Jupiter, Florida, Dec. 02, 2024 (GLOBE NEWSWIRE) — Jupiter Neurosciences, Inc. (Nasdaq: JUNS) (the “Company” or “Jupiter Neurosciences”), a clinical…

VANCOUVER, British Columbia, Dec. 02, 2024 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company” or “Rakovina Therapeutics”) a…

Phase 3 trial results published in European Journal of Heart Failure identify key target population for Mesoblast allogeneic cell therapyNEW…

HUNTSVILLE, Dec. 02, 2024 (GLOBE NEWSWIRE) — Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company, today announced…

AUSTIN, Texas, Dec. 02, 2024 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM” or the “Company”), a…

ADELAIDE, Australia, and CAMBRIDGE, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) — Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology…

All dollar amounts reflected in Canadian dollars unless otherwise statedVANCOUVER, British Columbia, Nov. 29, 2024 (GLOBE NEWSWIRE) — Rakovina Therapeutics…

BOSTON, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class…